Market, me included, had written CHM off. Not based on clinical data and progress but based on the financial sins committed by the chair since May'24 and lack of big pharma support.
If lessons have been learnt then a much higher MC will be possible. The market doesn't like investing in falling sp but in a rising sp. Turnaround or just a blimp, time will tell.
Ann: ADVENT-AML Phase 1B clinical trial update, page-50
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $15.69K | 3.919M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 21936206 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 24685267 | 27 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |